Clinical stage biopharmaceutical company Contineum Therapeutics Inc. (CTNM) is moving into a strategically significant window in its clinical development timeline, with multiple data readouts and trial initiations expected to shape its trajectory through the end of 2025 and beyond.
Stock Performance
We highlighted the stock, CTNM, to our subscribers on February 18, 2025, when it was trading around $7.81. The stock reached an intra-day high of $13.49 on September 19, 2025, representing a gain of over 72.7% from our published price.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.